PTGER1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL252356	0.79	20/20
SCHEMBL251373	0.71	20/20
SCHEMBL252598	0.69	20/20
SCHEMBL252089	0.56	20/20
SCHEMBL255383	0.56	20/20
SCHEMBL255384	0.56	20/20
SCHEMBL251678	0.55	20/20
SCHEMBL252051	0.55	20/20
SCHEMBL253117	0.55	20/20
SCHEMBL252139	0.50	20/20
SCHEMBL254655	0.52	19/20
SCHEMBL252003	0.51	16/20
SCHEMBL322569	0.49	13/20
SCHEMBL428409	0.41	12/20
SCHEMBL425801	0.40	10/20
SCHEMBL366512	0.51	9/20
SCHEMBL278545	0.44	9/20
SCHEMBL166264	0.44	9/20
Pinadoline (SCHEMBL122117)	0.72	8/20
SCHEMBL273511	0.47	8/20

Clinical trials — most relevant to PTGER1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes	PHASE4	UNKNOWN
Pharmacogenomics of Antiplatelet Response - I	PHASE4	COMPLETED
The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention	PHASE4	UNKNOWN
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)	PHASE4	COMPLETED
Termination of Pregnancy in Previous Scarred Uterus: PGE1 Versus Cervical Folleys	PHASE4	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar	PHASE2/PHASE3	UNKNOWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Montelukast for Early Life Wheezing	PHASE2/PHASE3	COMPLETED
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA	PHASE2/PHASE3	COMPLETED
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages	PHASE2/PHASE3	UNKNOWN
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs	PHASE3	COMPLETED
Addition of Aspirin to Standard of Care in Oral Cancer	PHASE2/PHASE3	COMPLETED
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine	PHASE2	WITHDRAWN
Celebrex for Pain Relief After Oral Surgery	PHASE2	COMPLETED
HTL0039732 in Participants With Advanced Solid Tumours	PHASE1/PHASE2	RECRUITING
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention	PHASE2	COMPLETED
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT	PHASE2	NOT_YET_RECRUITING
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors	PHASE1	COMPLETED
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)	EARLY_PHASE1	RECRUITING
Aspirin Resistance in Coronary Artery Disease	EARLY_PHASE1	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN
PGE2/IL-22 Pathway in Various Forms of Eczema	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS	nan	UNKNOWN
Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTGER1 binder may also engage these)

Protein	Name	Similarity
Q9BGL8	—	1.000	Q9BGL8 →
P35375	—	0.990	P35375 →
P70597	—	0.982	P70597 →
Q684M3	—	0.979	Q684M3 →
S1PR5	Sphingosine 1-phosphate receptor 5	0.976	landscape →
Q91X56	—	0.974	Q91X56 →
Q9JKM5	—	0.974	Q9JKM5 →
PTGIR	Prostacyclin receptor	0.963	landscape →
P34978	—	0.961	P34978 →
P79393	—	0.960	P79393 →
P30987	—	0.959	P30987 →
O54897	—	0.959	O54897 →
P32307	—	0.958	P32307 →
AVPR2	Vasopressin V2 receptor	0.958	landscape →
TBXA2R	Thromboxane A2 receptor	0.956	landscape →
P56486	—	0.956	P56486 →
GPR27	Probable G-protein coupled receptor 27	0.955	landscape →
Q9JJH3	—	0.955	Q9JJH3 →
O77808	—	0.954	O77808 →
Q00788	—	0.949	Q00788 →
P48044	—	0.948	P48044 →
O88721	—	0.946	O88721 →
S1PR4	Sphingosine 1-phosphate receptor 4	0.944	landscape →
P43252	—	0.944	P43252 →
MLNR	Motilin receptor	0.943	landscape →
Q8HYC3	—	0.943	Q8HYC3 →
GPR6	G-protein coupled receptor 6	0.941	landscape →
PTGDR	Prostaglandin D2 receptor	0.941	landscape →
Q95125	—	0.941	Q95125 →
P43253	—	0.939	P43253 →